DE60135358D1 - Uridin-therapie für patienten mit erhöhten purin-werten - Google Patents

Uridin-therapie für patienten mit erhöhten purin-werten

Info

Publication number
DE60135358D1
DE60135358D1 DE60135358T DE60135358T DE60135358D1 DE 60135358 D1 DE60135358 D1 DE 60135358D1 DE 60135358 T DE60135358 T DE 60135358T DE 60135358 T DE60135358 T DE 60135358T DE 60135358 D1 DE60135358 D1 DE 60135358D1
Authority
DE
Germany
Prior art keywords
patients
purin
values
increased
uridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60135358T
Other languages
English (en)
Inventor
Theodore M Page
Deborah Brewer
Charles D Moseley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
University of California
Original Assignee
Repligen Corp
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24768963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60135358(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repligen Corp, University of California filed Critical Repligen Corp
Application granted granted Critical
Publication of DE60135358D1 publication Critical patent/DE60135358D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60135358T 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin-werten Expired - Fee Related DE60135358D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/689,551 US6727231B1 (en) 2000-10-12 2000-10-12 Uridine therapy for patients with elevated purine levels
PCT/US2001/032051 WO2002030354A2 (en) 2000-10-12 2001-10-12 Uridine therapy for patients with elevated purine levels

Publications (1)

Publication Number Publication Date
DE60135358D1 true DE60135358D1 (de) 2008-09-25

Family

ID=24768963

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135358T Expired - Fee Related DE60135358D1 (de) 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin-werten

Country Status (8)

Country Link
US (1) US6727231B1 (de)
EP (1) EP1324761B1 (de)
JP (1) JP2004527460A (de)
AT (1) ATE404208T1 (de)
AU (2) AU1171102A (de)
CA (1) CA2425593A1 (de)
DE (1) DE60135358D1 (de)
WO (1) WO2002030354A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7440590B1 (en) * 2002-05-21 2008-10-21 University Of Kentucky Research Foundation System and technique for retrieving depth information about a surface by projecting a composite image of modulated light patterns
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
CA2580236A1 (en) * 2004-09-17 2006-03-23 Kissei Pharmaceutical Co., Ltd. Purinenucleoside derivative modified in 8-position and medical use thereof
MX2007003267A (es) * 2004-09-23 2007-05-23 Merz Pharma Gmbh & Co Kgaa Memantina para el tratamiento de trastornos de conducta en la infancia.
JP4778946B2 (ja) * 2007-12-03 2011-09-21 明治飼糧株式会社 血中尿酸値低下剤
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2019094596A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
ATE446097T1 (de) * 1998-07-31 2009-11-15 Massachusetts Inst Technology Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
EP1171137B1 (de) * 1999-02-23 2007-12-26 The Regents of the University of California Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen

Also Published As

Publication number Publication date
WO2002030354A2 (en) 2002-04-18
AU2002211711B2 (en) 2007-05-17
CA2425593A1 (en) 2002-04-18
EP1324761A4 (de) 2004-09-08
ATE404208T1 (de) 2008-08-15
US6727231B1 (en) 2004-04-27
AU1171102A (en) 2002-04-22
EP1324761B1 (de) 2008-08-13
WO2002030354A3 (en) 2002-07-11
EP1324761A2 (de) 2003-07-09
JP2004527460A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
HK1069767A1 (en) Methods for inhibiting ocular processes
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
BR0211986A (pt) 29-enóis de rapamicina
EP1401479A4 (de) Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
DE60135358D1 (de) Uridin-therapie für patienten mit erhöhten purin-werten
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
HK1112941A1 (en) Use of a33 antigens and jam-it a33
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
BR0206961A (pt) Elemento de mola e automóvel
MXPA04002562A (es) Combinacion de un pde-4 y nsaid.
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
EP2034030A3 (de) Neuartige Zusammensetzungen und Verfahren für Krebs
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee